ReviewNoradrenergic mechanisms in neurodegenerative diseases: a theory
Section snippets
Presentation of a theory
This review evaluates the evidence for a theory that a deficiency in the noradrenergic system of the brain, originating largely from cells in the locus coeruleus (LC), plays a decisive role in the progression of a family of neurodegenerative diseases that includes Parkinson's disease (PD) and Alzheimer's disease (AD). The theory as it was first proposed by Colpaert [107] focused primarily upon the role of noradrenergic deficits in the etiology of idiopathic PD (see also [106], [213], [367],
Anatomical locus
Important commonalities between AD and PD have been described [150], [156], [285], [424], [520]. Among the shared features are clinical signs, neuropathological findings, onset in the fifth or sixth decades of life, and loss of cells in the LC with consequent reduction in brain noradrenergic markers. These and other common elements have led some authors to conclude that a number of neurodegenerative diseases and syndromes are, in fact, different manifestations of a single disease process [24],
Clinico-pathological description
Idiopathic Parkinson's disease is a non-hereditary, chronic, and progressive neurodegenerative disorder of unknown cause that usually appears after the age of 50 and affects both sexes equally [298]. It is characterized by major reductions of dopaminergic cell numbers in the substantia nigra pars compacta, dopamine content in the striatum and noradrenergic cells in the LC [4], [248], [424]. Significant depletions (>80%) of noradrenaline in the substantia nigra pars compacta and reticulata and
Clinico-pathological description
Alzheimer's disease (AD) is a progressive neurodegenerative disorder of unknown etiology that most commonly affects persons over the age of 60. AD is characterized by the gradual onset and a steady decline in cognitive functions including memory for recent and remote events, language, judgment, attention, and executive functions such as planning and organizing. There is no cure for this disease and pharmacological treatments to date have met with only modest symptomatic improvement [36], [39],
The LC-noradrenergic system in other neurodegenerative diseases and conditions
The LC-noradrenergic system shows pathological changes in a number of other neurodegenerative diseases and conditions less common than PD and AD. Compared to age-matched controls, significant reductions in LC cell numbers have been reported in Huntington's disease [574] (but see Ref. [358]), progressive supranuclear palsy [299], [362], [518], corticobasal degeneration [218], dementia pugilistica [362], multiple system atrophy [386], [530], [553], Lewy body disease [508], Down's syndrome [212],
The LC-noradrenergic system in functional recovery after brain injury
Recovery of function after cortical injury, and the maintenance of that recovery in both animals and humans, appears to depend importantly upon the integrity of the LC-noradrenergic system. Rats sustaining a unilateral injury to the sensorimotor cortex (e.g., by ablation, undercutting or contusion) display a transient contralateral paresis (hemiplegia) such that their ability to traverse a narrow elevated beam is impaired. The training, adaptation and testing of animals in the beam-walking
Role of the LC-noradrenergic system in mechanisms putatively involved in neurodegenerative diseases
The postsynaptic net effect of noradrenaline is to enhance the responsivity of neurons to other powerful excitatory and inhibitory inputs while reducing spontaneous activity, thereby increasing the signal-to-noise ratio for trans-synaptic information transfer [480], [549], [550], [569]. The tonic firing rate of LC neurons, and therefore the release and availability of noradrenaline, is related to the presence of salient events, as well as arousal, vigilance, and attention [32], [33], [34], [35]
A rationale for the treatment of neurodegenerative disorders with alpha2-adrenoceptor antagonists
The activity of the LC-noradrenergic system is regulated by presynaptic inhibitory alpha2-adrenergic autoreceptors (for review, see Ref. [504]). By blocking these receptors, alpha2-adrenoceptor antagonists disinhibit the LC system, leading to an increase in LC neuronal activity and a consequent increase in noradrenaline synthesis and release [134]. Concomitantly, alpha2-adrenoceptor antagonists facilitate, by disinhibition, the activity of neuronal and glial targets downstream from the
Conclusions and perspectives
Noradrenaline assumes critical physiological roles in regulating cellular signaling and in governing compensatory and protective mechanisms that determine neuronal function and survival in the brain. Based on the evidence reviewed, a deficiency in the major noradrenergic nucleus of the brain, the locus coeruleus, is hypothesized to be a critical factor in determining the evolution of progressive degenerative disorders such as PD and AD. A treatment strategy using an alpha2-adrenoceptor
Further issues: caveats for experimental studies
In the interest of testing further the concepts exposed in this review, consideration is given here to some caveats regarding the pharmacological tools and lesioning procedures that are commonly used in studying noradrenergic influences on brain function in animal models. Certain of these caveats may apply also to clinical studies.
References (574)
Parkinson's disease: pathophysiology
Lancet
(1991)- et al.
Inflammation and Alzheimer's disease
Neurobiol. Aging
(2000) - et al.
Brain-derived neurotrophic factor increases survival and differentiated functions of rat septal cholinergic neurons in culture
Neuron
(1990) - et al.
Preservation of dopamine release in the denervated striatum
Neurosci. Lett.
(1989) Programmed cell death: the paths to suicide
Trends Neurosci
(1992)- et al.
Ultrastructural localization of beta-adrenergic receptor-like immunoreactivity in the cortex and neostriatum of rat brain
Brain Res.
(1987) - et al.
Perikaryal and synaptic localization of alpha 2A-adrenergic receptor-like immunoreactivity
Brain Res.
(1994) - et al.
Potential neurotrophic factors in the mammalian central nervous system: functional significance in the developing and aging brain
Int. Rev. Neurobiol.
(1990) Catecholamine modulation of prefrontal cortical cognitive function
Trends Cogn. Sci.
(1998)- et al.
Afferent regulation of locus coeruleus neurons: anatomy, physiology and pharmacology
Prog. Brain Res.
(1991)
Conditioned responses of monkey locus coeruleus neurons anticipate acquisition of discriminative behavior in a vigilance task
Neuroscience
Locus coeruleus and regulation of behavioral flexibility and attention
Prog. Brain Res.
Alzheimer's disease and the basal forebrain cholinergic system: relations to beta-amyloid peptides, cognition, and treatment strategies
Prog. Neurobiol.
On neurodegenerative diseases, models, and treatment strategies: lessons learned and lessons forgotten a generation following the cholinergic hypothesis
Exp. Neurol.
Effects of cholinergic depletion on experience-dependent plasticity in the cortex of the rat
Neuroscience
Effects of the alpha(2)-adrenoreceptor antagonist dexefaroxan on neurogenesis in the olfactory bulb of the adult rat in vivo: selective protection against neuronal death
Neuroscience
Do defects in mitochondrial energy metabolism underlie the pathology of neurodegenerative diseases?
Trends Neurosci.
Spatial working memory in rats: effects of monoaminergic antagonists
Pharmacol. Biochem. Behav.
The monoamine innervation of rat cerebral cortex: synaptic and nonsynaptic axon terminals
Neuroscience
The locus coeruleus-noradrenergic system: modulation of behavioral state and state-dependent cognitive processes
Brain Res. Brain Res. Rev.
Effect of the alpha 2 adrenoreceptor antagonist, idazoxan, on motor disabilities in MPTP-treated monkey
Prog. Neuropsychopharmacol. Biol. Psychiatry
Quisqualate lesions of rat NBM: selective effects on working memory in a double Y-maze
Brain Res. Bull.
Noradrenergic-induced expression of c-fos in rat cortex: neuronal localization
Neurosci. Lett.
Locus coeruleus lesions potentiate neurotoxic effects of MPTP in dopaminergic neurons of the substantia nigra
Brain Res.
Neurotrophin gene therapy in CNS models of trauma and degeneration
Prog. Brain Res.
Acetylcholine: a neurotransmitter for learning and memory?
Brain Res. Brain Res. Rev.
Intraventricular norepinephrine facilitates motor recovery following sensorimotor cortex injury
Pharmacol. Biochem. Behav.
Unilateral, but not bilateral, locus coeruleus lesions facilitate recovery from sensorimotor cortex injury
Pharmacol. Biochem. Behav.
Agonists of cholinergic and noradrenergic receptors facilitate synergistically the induction of long-term potentiation in slices of rat visual cortex
Brain Res.
Loss of developing cholinergic basal forebrain neurons following excitotoxic lesions of the hippocampus: rescue by neurotrophins
Exp. Neurol.
Beta-amyloid plaques in a model for sporadic Alzheimer's disease based on transgenic anti-nerve growth factor antibodies
Mol. Cell. Neurosci.
Effects of lesions to ascending noradrenergic neurones on performance of a 5-choice serial reaction task in rats; implications for theories of dorsal noradrenergic bundle function based on selective attention and arousal
Behav. Brain Res.
Partial lesion of the substantia nigra: relation between extent of lesion and rotational behavior
Brain Res.
Basic fibroblast growth factor (bFGF, FGF-2) immunoreactivity exists in the noradrenaline, adrenaline and 5-HT nerve cells of the rat brain
Neurosci. Lett.
Noradrenergic innervation of the substantia innominata: a light and electron microscopic analysis of dopamine beta-hydroxylase immunoreactive elements in the rat
Exp. Neurol.
Alterations in the locus coeruleus in dementias of Alzheimer's and Parkinson's disease
Prog. Brain Res.
A re-examination of the role of basal forebrain cholinergic neurons in spatial working memory
Neuropharmacology
Role of neurotrophic factors in Alzheimer's disease
Neurobiol. Aging
Changes in body temperature after administration of adrenergic and serotonergic agents and related drugs including antidepressants: II
Neurosci. Biobehav. Rev.
Partial injury to central noradrenergic neurons: reduction of tissue norepinephrine content is greater than reduction of extracellular norepinephrine measured by microdialysis
J. Neurosci.
Bilaterally diverging axon collaterals and contralateral projections from rat locus coeruleus neurons, demonstrated by fluorescent retrograde double labeling and norepinephrine metabolism
J. Neural Transm.
Changes in the brain catecholamines in patients with dementia of Alzheimer type
Br. J. Psychiatry
Neuronal plasticity and ageing processes in the frame of the ‘Red Queen Theory’
Acta Physiol. Scand.
Brain-derived neurotrophic factor enhances long-term potentiation in rat visual cortex
J. Neurosci.
Dopamine beta-hydroxylase deficiency impairs cellular immunity
Proc. Natl. Acad. Sci. U. S. A.
Methamphetamine-induced hyperthermia and dopaminergic neurotoxicity in mice: pharmacological profile of protective and nonprotective agents
J. Pharmacol. Exp. Ther.
Alternative excitotoxic hypotheses
Neurology
Methamphetamine-induced dopaminergic toxicity in mice. Role of environmental temperature and pharmacological agents
Ann. N.Y. Acad. Sci.
Characterization of dopaminergic midbrain neurons in a DBH:BDNF transgenic mouse
J. Comp. Neurol.
Activity-dependent activation of TrkB neurotrophin receptors in the adult CNS
Learn. Mem.
Cited by (370)
Adrenoceptors as potential target for add-on immunomodulatory therapy in multiple sclerosis
2023, Pharmacology and TherapeuticsThe Neurodegenerative Elderly Syndrome (NES) hypothesis: Alzheimer and Parkinson are two faces of the same disease
2022, IBRO Neuroscience ReportsMicrostructural integrity of the locus coeruleus and its tracts reflect noradrenergic degeneration in Alzheimer’s disease and Parkinson’s disease
2024, Translational Neurodegeneration